Tomography/magnetic resonance (PET/MR) imaging system
Royal Philips Electronics is announcing 510(k) clearance from the Food and Drug Administration (FDA) for the company’s first commercially available whole body positron emission tomography/magnetic resonance (PET/MR) imaging system, the Ingenuity TF PET/MR. This leading edge platform will redefine how medicine is practiced in the future by helping clinicians and researchers investigate novel personalized medicine and treatments for oncology, cardiology and neurology. The system’s prototype is on display at the Arab Health Exhibition & Congress that is taking place from the 23rd – 26th of January 2012, at the Dubai World Trade Centre.
It was previously thought that PET and MR scans were incompatible; however, Philips overcame the enormous technical hurdles, through advances in technology, to create a new class of hybrid imaging that will push the bounds of what’s possible in imaging. The system is designed to provide a state-of-the-art platform well into the future by facilitating the addition of new technologies as they become available.
Studies on the Ingenuity TF PET/MR have shown that bringing high fidelity PET and MR imaging together provides high quality diagnostic images. ’The PET/MR system will be useful to practitioners because of the highly anatomical and contrast images that can be acquired when you combine functional MR images with the metabolic information acquired by PET,” said Zahi Fayad, professor of radiology and medicine (cardiology), and director, Translational and Molecular Imaging Institute, at the Mount Sinai School of Medicine.
Clinical cases have already shown the advantages of being able to superimpose PET over MR images to help detect abnormalities in various organs. Previously, this was not possible because the two studies took place at different times, with different conditions and with different patient positions. In addition to the possibility of expanding clinical horizons as an advanced research tool, the system could also be used in a clinical setting to support a patient’s entire care cycle process from detection or diagnosis to long-term disease management.
The system features Philips’ proprietary Time-of-Flight (TOF) technology, Astonish TF, a technology for PET scanners that is designed to enhance image quality by reducing noise and providing increased sensitivity. It is combined with the superior soft-tissue contrast of 3T MR to image disease as it proliferates in soft tissue. As a testament to the system’s innovation, The Wall Street Journal selected the Ingenuity TF PET/MR as a 2011 runner-up in the medical device category for its annual Technology Innovation Awards.
“Over the years, the introduction of new medical imaging technologies has helped to expand clinical horizons,” said Gene Saragnese, executive vice-president and CEO, Imaging Systems, for Philips Healthcare. “The Ingenuity TF PET/MR is a state-of-the-art platform that will remain state-of-the-art as it continues to evolve over time to provide robust research and clinical value. This will change the way health care is practiced in the future.”
Mount Sinai and University Hospitals, Cleveland, will house the first Philips combined, whole body PET/MR systems in the U.S. “We are specifically interested in PET/MR because the combination is expected to provide a more advanced understanding of the processes taking place in vascular beds,” said Fayad.
With the program formally launched in 2007, Philips’ PET/MR system is one of the results of the company’s continuous investments in health care R&D even in adverse economic times. PET/MR is the embodiment of hybrid imaging, a major trend that is a growth driver of imaging procedure volumes. Philips was the first company to bring a PET/MR system to market when CE Mark in Europe was earned in January 2011. With FDA clearance, the system can now be marketed in the world’s largest health care market.
To date, Philips has sold 13 systems worldwide, and already installed systems at Mount Sinai School of Medicine in the U.S.; the University of Geneva in Switzerland; Helmholtz-Zentrum Dresden-Rossendorf (HZDR) in Dresden, Germany; Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Madrid, Spain; and Pusan National University in Korea. The system will be installed December 2011 at University Hospitals /Case Western Reserve University in Cleveland.